Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 50-54

  Parikh, Nisha I ^a,b   Gerschenson, Mariana ^a   Bennett, Kara ^a   Gangcuangco, Louie Mar M ^a   Lopez, Mary S ^a   Mehta, Nehal N ^c   Playford, Martin P ^c   Nakamoto, Beau K ^a,e   Seto, Todd B ^d   Chow, Dominic C ^a   Shikuma, Cecilia M ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d QUEEN S MEDICAL CENTER   (United States)

^e STRAUB CLINIC AND HOSPITAL   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol efflux capacity; HDL; Lipids; NMR spectroscopy; Oxidative phosphorylation

Indexed keywords

2 AMINOPURINE; CHOLESTEROL; CYTOCHROME C OXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXYGEN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COHORT ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIQUID SCINTILLATION COUNTING; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SECONDARY ANALYSIS; SMOKING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VIRUS LOAD; AGED; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; CYTOLOGY; GLUCOSE BLOOD LEVEL; INFLAMMATION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; CHOLESTEROL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; OXYGEN; PARTICLE SIZE; PHOSPHORYLATION;

EID: 84920733579     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.005     Document Type: Article

References (23)

1. Vigouroux C., Gharakhanian S., Salhi Y., Nguyen T.H., Chevenne D., Capeau J., Rozenbaum W. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic hiv-infected patients on highly active antiretroviral therapy (haart). Diabetes Metab. 1999, 25:225-232.
2. Kathiresan S., Otvos J.D., Sullivan L.M., Keyes M.J., Schaefer E.J., Wilson P.W., D'Agostino R.B., Vasan R.S., Robins S.J. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the framingham heart study. Circulation 2006, 113:20-29.
3. Duprez D.A., Kuller L.H., Tracy R., Otvos J., Cooper D.A., Hoy J., Neuhaus J., Paton N.I., Friis-Moller N., Lampe F., Liappis A.P., Neaton J.D. Lipoprotein particle subclasses, cardiovascular disease and hiv infection. Atherosclerosis 2009, 207:524-529.
4. Shen G.X. Mitochondrial dysfunction, oxidative stress and diabetic cardiovascular disorders. Cardiovasc Hematol. Disord. Drug Targets 2012, 12:106-112.
5. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K., Runge M.S. Mitochondrial integrity and function in atherogenesis. Circulation 2002, 106:544-549.
6. McPherson P.A., Young I.S., McKibben B., McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J.lipid Res. 2007, 48:86-95.
7. Christie W.W. Plasma Lipoproteins, Composition, Structure and Biochemistry 2013, AOSC Lipid Library.
8. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J.Clin. Lipidol. 2011, 5:105-113.
9. Gerschenson M., Kim C., Berzins B., Taiwo B., Libutti D.E., Choi J., Chen D., Weinstein J., Shore J., da Silva B., Belsey E., McComsey G.A., Murphy R.L. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J.Antimicrob. Chemother. 2009, 63:1244-1250.
10. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., French B.C., Phillips J.A., Mucksavage M.L., Wilensky R.L., Mohler E.R., Rothblat G.H., Rader D.J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N.Engl. J. Med. 2011, 364:127-135.
11. Mehta N.N., Li R., Krishnamoorthy P., Yu Y., Farver W., Rodrigues A., Raper A., Wilcox M., Baer A., DerOhannesian S., Wolfe M., Reilly M.P., Rader D.J., VanVoorhees A., Gelfand J.M. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012, 224:218-221.
12. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the hdl lipidome. J.lipid Res. 2013, 54:2950-2963.
13. Kim D.S., Marsillach J., Furlong C.E., Jarvik G.P. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 2013, 14:1495-1515.
14. Kim J.Y., Kim O.Y., Paik J.K., Kwon D.Y., Kim H.J., Lee J.H. Association of age-related changes in circulating intermediary lipid metabolites, inflammatory and oxidative stress markers, and arterial stiffness in middle-aged men. Age 2012, 18:18.
15. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
16. Kuller L., Arnold A., Tracy R., Otvos J., Burke G., Psaty B., Siscovick D., Freedman D.S., Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1175-1180.
17. Nisoli E., Clementi E., Carruba M.O., Moncada S. Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome?. Circ. Res. 2007, 100:795-806.
18. Ikewaki K., Terao Y., Ozasa H., Nakada Y., Tohyama J., Inoue Y., Yoshimura M. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. J.Atheroscler. Thromb. 2009, 16:51-56.
19. Fichtenbaum C.J., Yeh T.M., Evans S.R., Aberg J.A. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in actg 5087. J.Clin. Lipidol. 2010, 4:279-287.
20. Lefevre C., Auclair M., Boccara F., Bastard J.P., Capeau J., Vigouroux C., Caron-Debarle M. Premature senescence of vascular cells is induced by hiv protease inhibitors: implication of prelamin a and reversion by statin. Arterioscler. Thromb., Vasc. Biol. 2010, 30:2611-2620.
21. Larsen S., Stride N., Hey-Mogensen M., Hansen C.N., Bang L.E., Bundgaard H., Nielsen L.B., Helge J.W., Dela F. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J.Am. Coll. Cardiol. 2013, 61:44-53.
22. Hamoud S., Kaplan M., Meilin E., Hassan A., Torgovicky R., Cohen R., Hayek T. Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. Am. J. Med. Sci. 2013, 345:195-199.
23. Kaplon R.E., Gano L.B., Seals D.R. Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults. J.Appl. Physiol. 2014, 116:156-163.